- Former FDA Psychiatry Division Director Dr. Thomas Laughren joins BetterLife (BETR) as regulatory advisor
- Dr. Laughren was formerly Director for the Division of Psychiatry Products
- Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine
- BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products
- BetterLife Pharma Inc. (BETR) is down 2.91 per cent and is training at C$1.00 at 11:09 am ET
BetterLife Pharma Inc. (BETR) announced that Former FDA Psychiatry Division Director Dr. Thomas Laughren is joining BetterLife as Regulatory Advisor.
Dr. Laughren was formerly Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA.
Before joining the FDA in September 1983, Dr. Laughren was affiliated with the VA Medical Center in Providence, RI, and was on the faculty of the Brown University Program in Medicine.
Dr. Ahmad Doroudian, CEO of BetterLife, said,
“We are thrilled to have Dr. Laughren join the company as Regulatory Advisor. He brings invaluable psychiatric drug regulatory and development experience for our pipeline as we ramp up our IND-enabling activities.”
As Director for the Division of Psychiatry Products, Dr. Laughren oversaw the review of all psychiatric drug development activities conducted under INDs and reviewed all NDAs and supplements for new psychiatric drug claims.
He has authored and co-authored many papers and book chapters on regulatory and methodological issues about developing psychiatric drugs and is a frequent speaker at professional meetings on these same topics.
Dr. Laughren has received numerous awards for his regulatory accomplishments.
BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next-generation psychedelic products to treat mental disorders.
Utilizing drug delivery platform technologies, BetterLife is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.
BetterLife Pharma Inc. (BETR) is down 2.91 per cent and is training at C$1.00 at 11:09 am ET.
